Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 254-260

  Wang, Yaopeng ^a   Tao, Hao ^a   Yu, Xuyi ^b   Wang, Zhan ^b   Wang, Mingzhao ^a  

^a QINGDAO UNIVERSITY   (China)

^b Center Hospital of Qingdao City   (China)

Author keywords

Bone metastases; Non small cell lung cancer; Skeletal related event; Strontium 89; Zoledronic acid

Indexed keywords

STRONTIUM 89; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT MONITORING; POST TREATMENT SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; SPINAL CORD COMPRESSION; STRONTIUM;

EID: 84879930218     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.09.001     Document Type: Article

References (39)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics CA Cancer J Clin 2009 2009 225 249
2. J. Ferlay, H.R. Shin, F. Bray Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer http://globocan.iarc.fr Accessed: October 9, 2012
3. G. D'Addario, M. Fruh, M. Reck Metastatic non-small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 2010 116 119
4. National Comprehensive Cancer Network NCCN Clinical Practice guidelines in oncology. Nonsmall Cell Lung Cancer, version 3.2012 http://www.nccn.org Accessed: April 11, 2012
5. K. Zarogoulidis, E. Boutsikou, P. Zarogoulidis The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis Int J Cancer 125 2009 1705 1709
6. V. Hirsh Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer Clin Lung Cancer 10 2009 223 229
7. R.D. Pockett, D. Castellano, P. McEwan The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain Eur J Cancer Care 19 2010 755 760
8. R. Coleman, J. Brown, E. Terpos Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions Cancer Treat Rev 34 2008 629 639
9. Logman JFS, Botteman MF, Kaura S. Cost-effectiveness assessment of zoledronic acid (ZOL) relative to placebo (PBO) in the treatment of lung cancer patients with skeletal metastases in five European countries. Paper presented at: 12th Annual European Congress International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Health Care Decision Making in Europe: From Patients to Populations. October 24-27, 2009; Paris, France.
10. L. Costa, X. Badia, E. Chow Impact of skeletal complications on patients' quality of life, mobility, and functional independence Support Care Cancer 16 2008 879 889
11. M.F. Botteman, I. Foley, A.A. Marfatia Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: the case of the United Kingdom (UK) J Clin Oncol 25 2007 6617
12. A.D. Joshi, J.A. Carter, M.F. Botteman Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom Clin Ther 33 2011 291 304
13. N.S. Tchekmedyian, Y.-M. Chen, F. Saad Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration resistant prostate cancer, lung cancer, or other solid tumors Cancer Invest 28 2010 844 855
14. Hatoum HT, Sin S, Lipton A, et al. Persistency on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in lung cancer patients. Paper presented at the 13th World Congress on Lung Cancer. July 31-August 1, 2009; San Francisco, CA.
15. M. Aapro, P.A. Abrahamsson, J.J. Body Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
16. F. Saad, A. Lipton Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease Semin Oncol 34 2007 17 23
17. M. Goffinet, M. Thoulouzan, A. Pradines Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells BMC Cancer 6 2006 60
18. T. Yuasa, S. Kimura, E. Ashihara Zoledronic acid - a multiplicity of anti-cancer action Curr Med Chem 14 2007 2126 2135
19. L.S. Rosen, D. Gordon, S. Tchekmedyian Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors Study Group J Clin Oncol 21 2003 3150 3157
20. C. Langer, V. Hirsh Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates Lung Cancer 67 2010 4 11
21. F. De Marinis, W. Eberhardt, P.G. Harper Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel J Thorac Oncol 4 2009 1280 1288
22. F.M. Paes, A.N. Serafini Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain Semin Nucl Med 40 2010 89 104
23. P.M. Quilty, D. Kirk, J.J. Bolger A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31 1994 33 40
24. N. Firusian, P. Mellin, C.G. Schmidt Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report J Urol 116 1976 764 768
25. A.J. Taylor Jr Strontium-89 for the palliation of bone pain due to metastatic disease J Nucl Med 35 1994 2054 2061
26. M.G. Lam, J.M. de Klerk, P.P. van Rijk Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases Anticancer Agents Med Chem 7 2007 381 397
27. G.M. Blake, M.A. Zivanovic, R.M. Blaquiere Strontium-89 therapy: measurement of absorbed dose to skeletal metastases J Nucl Med 29 1988 549 557
28. G. Storto, M. Klain, G. Paone Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases Bone 39 2006 35 41
29. C.S. Marcus, S. Saeed, A. Mlikotic Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP Clin Nucl Med 27 2002 427 430
30. M. Papotti, T. Kalebic, M. Volante Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study J Clin Oncol 24 2006 4818 4824
31. A. Dafermou, P. Colamussi, M. Giganti A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer Eur J Nucl Med 28 2001 788 798
32. Y. Kimura, K. Hamamoto, M. Furudate Effectiveness of the radioactive strontium (89Sr) chloride agent, SMS.2P for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial. [in Japanese] Kaku Igaku 33 1996 1347 1358
33. G. Bauman, M. Charette, R. Reid Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review Radiother Oncol 75 2005 258 270
34. F. Saad, J. Eastham Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer Urology 76 2010 1175 1181
35. V. Hirsh, P.P. Major, A. Lipton Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 2008 228 236
36. H.L. Neville-Webbe, M. Grant, R.E. Coleman Potential anticancer properties of bisphophonates Semin Oncol 37 2010 S53 S65
37. R. Mahtani, R. Khan, M. Jahanzeb The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer Clin Lung Cancer 12 2011 26 32
38. L. Costa, P. Harper, R.E. Coleman Anticancer evidence for zoledronic acid across the cancer continuum Crit Rev Oncol Hematol 77 2011 31 37
39. E. Terpos Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum Crit Rev Oncol Hematol 77 2011 1 2